Anthracyclines remain a cornerstone of therapy for lymphoproliferative diseases eratie(LPD) but are associated with cardiovascular toxicity (CVT). While myocardial injury is well studied, anthracycline-induced vascular toxicity and endothelial dysfunction as early manifestations of cardiovascular damage remain insufficiently explored, particularly in patients with low or intermediate baseline CVT-risk, who do not meet criteria for cardioprotective therapy according to current guidelines. Identification of early biomarkers of subclinical vascular injury is, therefore, of major importance in cardio-oncology.
To assess the diagnostic and prognostic value of endothelin-1 (ET-1) for detection and progression of endothelial dysfunction in lymphoma patients with low and intermediate CVT-risk receiving anthracycline-based chemotherapy.
This prospective study included 37 patients with newly diagnosed LPDs (median age 46 [34–62] years) treated with anthracycline-containing chemotherapy. Baseline CVT-risk was assessed using HFA-ICOS scores; all patients were classified as low or intermediate risk and did not require cardioprotective therapy. Serum ET-1 levels were measured by ELISA before treatment initiation and after 3 chemotherapy cycles (cumulative anthracycline dose 270 mg/m²). Endothelial function was evaluated using digital photoplethysmography (ANGIOSCAN-01), assessing phase shift (PS) and occlusion index (OI). ROC analysis was performed to evaluate prognostic performance.
Baseline ET-1 levels were elevated and increased significantly after 3 cycles of chemotherapy (5.39 [4.6–7.21] vs 7.19 [5.9–11.6] pg/mL; p = 0.003). This was accompanied by a significant decline in endothelial function parameters: PS (normal >10 ms) decreased from 8.6 [7.2–10.2] to 6.3 [5.2–9.8] ms (p = 0.014), and OI (normal >1.8) decreased from 1.7 [1.4–1.9] to 1.5 [1.2–1.9] (p = 0.004). ROC analysis demonstrated good prognostic performance of ET-1 for endothelial dysfunction: AUC 0.772 for PS (95% CI: 0.582-0.962, p=0.031) and 0.743 for OI (95% CI: 0.532-0.954, p=0.048).
Endothelin-1 is a promising early diagnostic and prognostic biomarker of subclinical anthracycline-induced vascular toxicity in lymphoma patients with low and intermediate CVT-risk. ET-1 assessment may facilitate early risk reclassification and optimization of cardio-oncology surveillance strategies.
R. Alieva, K. Fozilov, M. Yakhyoeva et al.· European Heart Journal, Supp...· 0 citations
Current cardio-oncology surveillance strategies are primarily focused on patients with high or very high baseline cardiovascular (CV) toxicity risk. Patients with initially low risk are generally considered a clinically favorable group and therefore undergo less intensive monitoring. This approach may lead to underestimation of early, clinically silent vascular alterations developing during chemotherapy.
To assess changes in lipid profile parameters in oncohematological patients with low baseline cardiovascular toxicity risk and to determine their value for identifying early subclinical vascular toxicity and substantiating early initiation of cardioprotective therapy.
This study included 59 patients with B-cell hematological malignancies. According to ESC guidelines on cardio-oncology (2022), patients were stratified into low/moderate (n=42) and high/very high (n=17) CV toxicity risk groups. Lipid profiles were assessed at baseline and after three cycles of chemotherapy. Patients in the high/very high-risk group received standard cardioprotective therapy, including ACE inhibitors/ARBs, beta-blockers, and statins.
The median age in low risk group was 51.5 years [41.75; 63.00] (50% men), in high/very high risk group was 72 years [65.00; 75.00] (47.1% men). Most patients in both groups had traditional CV risk factors: obesity (n=11, 19%), smoking (n=12, 20%), diabetes mellitus (n=8, 13%), hypertension (n=24, 41%), and dyslipidemia (n=30, 51%), 8 patients in high/very high risk group were diagnosed with CAD. In patients with low and moderate baseline CV risk, a statistically significant deterioration in lipid profile was observed during chemotherapy, including increases in total cholesterol (4.54 vs. 5.43 mmol/L), low-density lipoprotein cholesterol (3.1 vs. 3.95 mmol/L), and triglycerides (0.86 vs. 1.01 mmol/L). All changes were highly significant (p<0.01). These findings are consistent with the development of subclinical endothelial dysfunction and early vascular toxicity, despite the absence of overt clinical manifestations of vasculotoxicity. In contrast, no significant changes in lipid parameters were observed in the high and very high-risk group, despite a greater baseline cardiovascular burden.
Patients with low baseline cardiovascular toxicity risk may develop early metabolic signs of subclinical vascular toxicity at the initial stages of chemotherapy. Dynamic assessment of lipid profile represents a simple and clinically applicable tool for early detection of vascular injury. The absence of high baseline cardiovascular risk does not preclude early vascular toxicity, supporting the rationale for considering earlier initiation of cardioprotective therapy in this patient population.
R. Alieva, K. Fozilov, M. Yakhyoeva et al.· European Heart Journal, Supp...· 0 citations